personalized synthetic long peptide vaccine
Biologicalexperimental
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 29, 2015 (NCT02427581)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- personalized synthetic long peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05933720 | N/A | Apr 1, 2023 | Ryazan State Medical University |
| NCT05741242 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2022 | Jaime Leandro Foundation for Therapeutic Cancer Vaccines |
| NCT03606967 | Phase 2 | Oct 1, 2018 | National Cancer Institute (NCI), Yale University |
| NCT03223103 | Phase 1 | Mar 1, 2018 | NovoCure Ltd., Yeshiva University |
| NCT03166254 | Phase 1 | Aug 31, 2017 | Washington University in St. Louis |
| NCT03121677 | Phase 1 | Jul 1, 2017 | Washington University in St. Louis |
| NCT02427581 | Phase 1 | Sep 29, 2015 | Washington University in St. Louis |
| NCT06963697 | N/A | — | Jaime Leandro Foundation for Therapeutic Cancer Vaccines |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Washington University in St. Louis | Academic/Hospital | 3 | 3 | 1 | 2015 |
| Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Academic/Hospital | 2 | 2 | 2 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2018 |
| NovoCure Ltd. | For profit | 1 | 0 | 1 | 2018 |
| Ryazan State Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Yeshiva University | Academic/Hospital | 1 | 1 | 1 | 2018 |
7 organizations
Page 1 / 1